A new system for targeted delivery of doxorubicin into tumor cells.

Yabbarov N.G., Posypanova G.A., Vorontsov E.A., Obydenny S.I., Severin E.S.
Тип документаJournal Article
Дата публикации2013-06-25
Название журналаJournal of Controlled Release
Квартиль по SCImagoQ1
Квартиль по Web of ScienceQ1
Импакт-фактор 202111.47
ISSN01683659, 18734995
Pharmaceutical Science
Краткое описание
The use of vector molecules for the targeted delivery of antitumor drugs provides their selectivity for cancer cells. The recombinant receptor-binding fragment of alpha-fetoprotein (rAFP3D) was used as a vector molecule. The specific receptor of alpha-fetoprotein is a universal tumor marker, being expressed on the surface of many tumor cells, but not in normal human tissues. And rAFP3D includes the receptor binding cite of AFP. A three-component delivery system including vector protein rAFP3D, PAMAM G2 dendrimer and antitumor antibiotic doxorubicin (Dox) was synthesized. The attachment of two dendrimer molecules to the vector protein did not affect the effectiveness of rAFP3D binding to AFP receptor on the surface of tumor cells nor the effectiveness of receptor-mediated endocytosis. Dox was conjugated with G2 via cis-aconitic anhydride (acid labile linker). The in vitro Dox release study showed that the conjugate was stable at neutral pH but was labile at pH<6. The Dox release was correlated with the intracellular distribution of conjugate in tumor cells. The rAFP3D-G2-Dox conjugate demonstrated a high cytotoxic activity against human ovarian adenocarcinoma cell lines: Dox-sensitive SKOV3 cells and Dox-resistant SKVLB cells and was low-toxic against human peripheral blood lymphocytes. Based on our findings, we may conclude that it is possible to significantly increase the effectiveness of Dox delivery to tumor cells by using the targeted delivery system comprising the recombinant third domain rAFP3D as a vector molecule.
Пристатейные ссылки: 23
Цитируется в публикациях: 42
Targeted delivery of doxorubicin through conjugation with EGF receptor–binding peptide overcomes drug resistance in human colon cancer cells
Ai S., Jia T., Ai W., Duan J., Liu Y., Chen J., Liu X., Yang F., Tian Y., Huang Z.
Q1 British Journal of Pharmacology 2013 цитирований: 24
Efficient refolding of a hydrophobic protein with multiple S-S bonds by on-resin immobilized metal affinity chromatography.
Sharapova O.A., Yurkova M.S., Laurinavichyute D.K., Andronova S.M., Fedorov A.N., Severin S.E., Severin E.S.
Q1 Journal of Chromatography A 2011 цитирований: 11
Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells
Łubgan D., Jóźwiak Z., Grabenbauer G., Distel L.
Q1 Cellular and Molecular Biology Letters 2009 цитирований: 33
Open Access
Open access
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
Stasi R.
Q1 Expert Opinion on Biological Therapy 2008 цитирований: 42
Recombinant alpha-fetoprotein C-terminal fragment: The new recombinant vector for targeted delivery
Posypanova G.A., Gorokhovets N.V., Makarov V.A., Savvateeva L.V., Kireeva N.N., Severin S.E., Severin E.S.
Q1 Journal of Drug Targeting 2008 цитирований: 24
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Ross H.J., Hart L.L., Swanson P.M., Rarick M.U., Figlin R.A., Jacobs A.D., McCune D.E., Rosenberg A.H., Baron A.D., Grove L.E., Thorn M.D., Miller D.M., Drachman J.G., Rudin C.M.
Q1 Lung Cancer 2006 цитирований: 31
Dendrimers in biomedical applications--reflections on the field.
Q1 Advanced Drug Delivery Reviews 2005 цитирований: 1265
Dendrimers: a new class of nanoscopic containers and delivery devices
Aulenta F., Hayes W., Rannard S.
Q1 European Polymer Journal 2003 цитирований: 331
Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.
Kratz F., Drevs J., Bing G., Stockmar C., Scheuermann K., Lazar P., Unger C.
Q2 Bioorganic and Medicinal Chemistry Letters 2001 цитирований: 62
Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation.
Reddy J.A., Low P.S.
Q1 Journal of Controlled Release 2000 цитирований: 124
Q2 Cell Biology International 1997 цитирований: 9
Carrier-protein-mediated enhancement of fatty-acid binding and internalization in human T-lymphocytes.
Uriel J., Torres J., Anel A.
Q2 Biochimica et Biophysica Acta - Molecular Cell Research 1994 цитирований: 11
Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.
Denizot F., Lang R.
Q2 Journal of Immunological Methods 1986 цитирований: 3352
A New Class of Polymers: Starburst-Dendritic Macromolecules
Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J., Smith P.
Q1 Polymer Journal 1985 цитирований: 2783
cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate.
Shen W., Ryser H.J.
Q1 Biochemical and Biophysical Research Communications 1981 цитирований: 216
1. Yabbarov N. G. и др. A new system for targeted delivery of doxorubicin into tumor cells // Journal of Controlled Release. 2013. Т. 168. № 2. С. 135–141.


DO - 10.1016/j.jconrel.2013.03.007

UR - http://dx.doi.org/10.1016/j.jconrel.2013.03.007

TI - A new system for targeted delivery of doxorubicin into tumor cells

T2 - Journal of Controlled Release

AU - Yabbarov, N.G.

AU - Posypanova, G.A.

AU - Vorontsov, E.A.

AU - Obydenny, S.I.

AU - Severin, E.S.

PY - 2013

DA - 2013/06

PB - Elsevier BV

SP - 135-141

IS - 2

VL - 168

SN - 0168-3659

ER -

BibTex |


doi = {10.1016/j.jconrel.2013.03.007},

url = {https://doi.org/10.1016%2Fj.jconrel.2013.03.007},

year = 2013,

month = {jun},

publisher = {Elsevier {BV}},

volume = {168},

number = {2},

pages = {135--141},

author = {N.G. Yabbarov and G.A. Posypanova and E.A. Vorontsov and S.I. Obydenny and E.S. Severin},

title = {A new system for targeted delivery of doxorubicin into tumor cells},

journal = {Journal of Controlled Release}


Yabbarov, N. G., et al. “A New System for Targeted Delivery of Doxorubicin into Tumor Cells.” Journal of Controlled Release, vol. 168, no. 2, June 2013, pp. 135–41. Crossref, https://doi.org/10.1016/j.jconrel.2013.03.007.